All In Biotech

Drug Trial Radar · NCT00199394

A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease

A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy.

Last checked: Nov 19, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 405 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

405

Actual

Start

Nov 2004

Primary completion

Oct 2005

Study completion Nov 2005

Sponsor

Lead sponsor
Kyowa Kirin Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Kyowa Hakko Kirin UK, Ltd.
First posted
Sep 20, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of 40 mg a day of istradefylline (KW-6002) for reducing the percentage of awake time spent in the OFF state in patients with advanced Parkinson's disease treated with levodopa.

Conditions

  • Parkinson's Disease

Interventions

  • Istradefylline (KW-6002)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OFF time assessed by patient diaries at endpoint.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kyowa Hakko UK Ltd.

    Slough, Berkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.